Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Operating Expenses (2019 - 2025)

Historic Operating Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $265.9 million.

  • BridgeBio Pharma's Operating Expenses rose 3672.17% to $265.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $963.7 million, marking a year-over-year increase of 2644.3%. This contributed to the annual value of $814.9 million for FY2024, which is 3214.05% up from last year.
  • BridgeBio Pharma's Operating Expenses amounted to $265.9 million in Q3 2025, which was up 3672.17% from $244.8 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Operating Expenses high stood at $265.9 million for Q3 2025, and its period low was $128.0 million during Q1 2023.
  • In the last 5 years, BridgeBio Pharma's Operating Expenses had a median value of $175.4 million in 2022 and averaged $178.9 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 2701.86% in 2023, then surged by 6468.37% in 2024.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Operating Expenses stood at $178.5 million in 2021, then fell by 26.55% to $131.1 million in 2022, then soared by 36.66% to $179.2 million in 2023, then rose by 29.44% to $231.9 million in 2024, then increased by 14.66% to $265.9 million in 2025.
  • Its Operating Expenses was $265.9 million in Q3 2025, compared to $244.8 million in Q2 2025 and $221.0 million in Q1 2025.